Acadia Pharmaceuticals diskutieren
Acadia Pharmaceuticals
WKN: 603035 / Symbol: ACAD / Name: ACADIA Pharm / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
23,21 €
-1,30 %
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at UBS Group AG from $25.00 to $23.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at Citigroup Inc. from $30.00 to $23.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $28.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at Needham & Company LLC from $27.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at HC Wainwright from $27.00 to $32.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at BMO Capital Markets from $24.00 to $28.00. They now have an "outperform" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $26.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at Robert W. Baird from $28.00 to $31.00. They now have an "outperform" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft to $35.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at JPMorgan Chase & Co. from $26.00 to $30.00. They now have an "overweight" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at Royal Bank Of Canada from $26.00 to $38.00. They now have an "outperform" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at JPMorgan Chase & Co. from $30.00 to $34.00. They now have an "overweight" rating on the stock.
Ratings data for ACAD provided by MarketBeat
Neueste Beiträge
UBS_Group_AG in Enterprise Products Partners L.p. diskutieren